Remdesivir
Remdesivir + Corticosteroids Boost Survival in COVID-19 Patients With COPD
Early initiation of remdesivir (Veklury, Gilead Sciences) and corticosteroids in patients with COPD and COVID-19 ...
AUGUST 8, 2025
Veklury Reduces Mortality in Immunocompromised People With COVID-19
Veklury can have significant benefits for immunocompromised people with COVID-19, reducing mortality by 30%.
FEBRUARY 14, 2024
FDA Grants New Indication for Veklury to Treat COVID-19 in People With Hepatic Impairment
The FDA granted a supplemental new drug application for the use of remdesivir with no dose adjustments to treat ...
AUGUST 25, 2023
FDA Expands Indication for Veklury to Treat COVID-19 Patients With Renal Impairment
With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across ...
JULY 14, 2023
Remdesivir Reduces Readmission Risk by 16% Among Immunocompromised Patients With COVID-19
Remdesivir (Veklury, Gilead) may reduce risk for hospital readmission by as much as 16% among immunocompromised ...
APRIL 21, 2023
Remdesivir-Resistant Version of COVID-19 Detected in Organ Transplant Recipients
Two kidney transplant patients treated with immunosuppressive drugs, and who later had a lengthy COVID-19 ...
NOVEMBER 7, 2022
FDA Approves Veklury, First COVID-19 Treatment for Young Children
The FDA expanded the approval of the COVID-19 drug remdesivir (Veklury, Gilead) to include pediatric patients 28 ...
APRIL 26, 2022
Remdesivir Resistance Found in Immunocompromised Patient
Yale researchers said the discovery raised concerns about the emergence of drug resistance in COVID-19 patients, ...
MARCH 23, 2022
FDA Expands Use of Veklury for Mild to Moderate COVID-19
Previously limited to hospitalized patients, The FDA expands use of remdesivir to the outpatient setting.
JANUARY 24, 2022
FDA Authorizes Baricitinib Alone as COVID-19 Treatment
The FDA revised the emergency use authorization (EUA) for baricitinib to enable its use alone for the treatment of ...
JULY 29, 2021
Remdesivir Halves Mortality in COVID Patients
COVID-19 patients treated with Veklury saw a 54% lower mortality risk at 28 days than those receiving ...
JULY 15, 2021
IDSA Gives Bamlanivimab a Conditional ‘No-Go’ for Routine Use in COVID-19 Recommendations
However, IDSA panel says remdesivir could reduce time to discharge—an important consideration when beds are ...
NOVEMBER 25, 2020
